Enanta Pharmaceuticals, Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 9 name spellings.
13
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18, 2026
- 3 fees due Jan 21 to 30, 2027 · next Jan 21
- 2 fees due Feb 8 to 28, 2027 · next Feb 8
- 3 fees due Mar 3 to 19, 2027 · next Mar 3
- 7 fees due Apr 1 to 30, 2027 · next Apr 1
- 2 fees due May 12 to 24, 2027 · next May 12
- 5 fees due Jun 5 to 30, 2027 · next Jun 5
- 3 fees due Jul 2 to 26, 2027 · next Jul 2
- 4 fees due Aug 6 to 27, 2027 · next Aug 6
- 4 fees due Sep 5 to 24, 2027 · next Sep 5
- 5 fees due Oct 2 to 30, 2027 · next Oct 2
- 1 fee due Nov 7, 2027The maintenance fee for Spiropyrrolidine derived antiviral agents (US 11,976,084) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 20, 2026
- 6 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,538,225 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine In force · From the USPTO record | In force | From the USPTO record | |
| US 7,589,067 | 6, 11-bridged tricyclic macrolides In force · From the USPTO record | In force | From the USPTO record | |
| US 7,563,877 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 In force · From the USPTO record | In force | From the USPTO record | |
| US 7,622,452 | C-9 alkenylidine bridged macrolides In force · From the USPTO record | In force | From the USPTO record | |
| US 7,906,513 | Hydrazide-containing hepatitis C serine protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,951,998 | Quinoxaline-containing compounds as hepatitis C virus inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 7,842,813 | Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine In force · From the USPTO record | In force | From the USPTO record | |
| US 8,193,346 | Process for Making Macrocyclic Oximyl Hepatitis C Protease Inhibitors In force · High confidence | In force | High confidence | |
| US 9,156,886 | Cyclosporin analogues for preventing or treating hepatitis C infection In force · From the USPTO record | In force | From the USPTO record | |
| US 8,101,643 | Novel Benzimidazole Derivatives In force · High confidence | In force | High confidence |
Also on record, not counted in the 144: 4 patents in force now held by others · 131 lapsed for an unpaid fee · 25 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 6 abandoned · 21 no status recorded